[ 18F]fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: An illustrative case

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages

  Chuang, Hubert H ^a   Deniz, Ferhat ^a   Sircar, Kanishka ^a   Jimenez, Camilo ^a   De Celis, Carlos Rubin ^b   Wood, Christopher G ^a   Habra, Mouhammed Amir ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETININ; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; INHIBIN; KI 67 ANTIGEN; MITOTANE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT;

ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPHADENOPATHY; MALE; METASTASIS; NECROSIS; NEPHRECTOMY; PATHOLOGY; PRIORITY JOURNAL; THROMBECTOMY; THROMBUS; ULTRASOUND; ADJUVANT THERAPY; ADRENAL CORTEX TUMOR; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84866608505     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.6710     Document Type: Article

References (17)

1. Dackiw AP, Lee JE, Gagel RF, et al: Adrenal cortical carcinoma. World J Surg 25:914-926, 2001
2. Delbeke D: Oncological applications of FDG PET imaging. J Nucl Med 40:1706-1715, 1999
3. Maurea S, Mainolfi C, Bazzicalupo L, et al: Imaging of adrenal tumors using FDG PET: Comparison of benign and malignant lesions. AJR Am J Roentgenol 173:25-29, 1999
4. Boland GW, Goldberg MA, Lee MJ, et al: Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 194:131-134, 1995
5. Erasmus JJ, Patz EF Jr, McAdams HP, et al: Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168:1357-1360, 1997
6. Leboulleux S, Dromain C, Bonniaud G, et al: Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: A prospective comparison with computed tomography. J Clin Endocrinol Metab 91:920-925, 2006
7. Antoch G, Saoudi N, Kuehl H, et al: Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 22:4357-4368, 2004
8. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
9. Wahl RL, Jacene H, Kasamon Y, et al: From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S-150S, 2009 (suppl 1)
10. Young H, Baum R, Cremerius U, et al: Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations - European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773-1782, 1999
11. Wahl RL, Zasadny K, Helvie M, et al: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 11:2101-2111, 1993
12. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al: 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma 39:543-553, 2000
13. Lee DH, Kim SK, Lee HY, et al: Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol 4:816-821, 2009
14. Gayed I, Vu T, Iyer R, et al: The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45:17-21, 2004
15. Kamiyama Y, Aihara R, Nakabayashi T, et al: 18F-fluorodeoxyglucose positron emission tomography: Useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 29:1429-1435, 2005
16. Vesselle H, Salskov A, Turcotte E, et al: Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol 3:971-978, 2008
17. Mikhaeel NG, Hutchings M, Fields PA, et al: FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16:1514-1523, 2005